Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · colon-landscapes@1

SRR12475129

—

73fdb611-a868-592f-b8d8-e0cbb926eff3

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ANDROGEN_RESPONSE+0.370
  • G2M_CHECKPOINT+0.350
  • PROTEIN_SECRETION+0.350
  • E2F_TARGETS+0.310
  • MTORC1_SIGNALING+0.310
  • UV_RESPONSE_DN+0.290
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.260
  • SPERMATOGENESIS+0.220
  • INFLAMMATORY_RESPONSE+0.160
  • GLYCOLYSIS+0.140

Top 10 suppressed

  • WNT_BETA_CATENIN_SIGNALING-0.370
  • INTERFERON_ALPHA_RESPONSE-0.360
  • TNFA_SIGNALING_VIA_NFKB-0.280
  • P53_PATHWAY-0.270
  • MYC_TARGETS_V2-0.250
  • MYOGENESIS-0.250
  • DNA_REPAIR-0.240
  • APOPTOSIS-0.230
  • UV_RESPONSE_UP-0.230
  • INTERFERON_GAMMA_RESPONSE-0.220

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1DRR168595
bladder-landscape@3
——0.726
2TCGA-BH-A1FM-01A-11R-A13Q-07
breast-umap@18
—B0.715
3MBCProject_5953_T1_RNA
breast-umap@18
—B0.708
4MNG727
mng-umap@100
——0.703
5TCGA-D8-A1XS-01A-11R-A14M-07
breast-umap@18
—B0.684
6b503bcc9-714d-40aa-8709-3b4577ce8007
colon-landscapes@1
——0.660
7R397
bladder-landscape@3
——0.651
8TCGA-A8-A07B-01A-11R-A00Z-07
breast-umap@18
—C0.645
9SJEPD030795_D2.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.643
1065460
medullo-epn-umap@date-based
EPNSupratentorial EPN0.642

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ANDROGEN_RESPONSE0.370Inavolisib— uncovered
G2M_CHECKPOINT0.350Inavolisib— uncovered
PROTEIN_SECRETION0.350Remibrutinib— uncovered
E2F_TARGETS0.310Inavolisib— uncovered
MTORC1_SIGNALING0.310Inavolisib— uncovered
UV_RESPONSE_DN0.290Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.260Inavolisib— uncovered
SPERMATOGENESIS0.220Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.160Idelalisib— uncovered
GLYCOLYSIS0.140Inavolisib— uncovered
ANGIOGENESIS0.100Remibrutinib— uncovered
CHOLESTEROL_HOMEOSTASIS0.100Remibrutinib— uncovered
MITOTIC_SPINDLE0.090Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.080Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.070Inavolisib— uncovered
KRAS_SIGNALING_UP0.070Inavolisib— uncovered
BILE_ACID_METABOLISM0.050Inavolisib— uncovered
HEME_METABOLISM0.040Temsirolimus— uncovered
ESTROGEN_RESPONSE_LATE0.030Idelalisib— uncovered
COMPLEMENT0.020Inavolisib— uncovered